ODAN-ARIPIPRAZOLE SOLUTION DIN 02566788
Health Canada record
| Active ingredient(s) | ARIPIPRAZOLE 1 MG |
|---|---|
| Dosage form | Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N05AX12 ARIPIPRAZOLE |
| Original market date | 21-Jul-2026 |
| Current status date | 21-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Odan Laboratories Ltd. — licence 100025, currently licensed, last inspection rating C (2024-03-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ARIPIPRAZOLE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02322404 | ABILIFY | OTSUKA PHARMACEUTICAL CO LTD | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02322412 | ABILIFY | OTSUKA PHARMACEUTICAL CO LTD | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02322374 | ABILIFY | OTSUKA PHARMACEUTICAL CO LTD | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02322382 | ABILIFY | OTSUKA PHARMACEUTICAL CO LTD | Tablet | ARIPIPRAZOLE 5 MG | Marketed |
| 02322390 | ABILIFY | OTSUKA PHARMACEUTICAL CO LTD | Tablet | ARIPIPRAZOLE 10 MG | Marketed |
| 02554569 | ABILIFY ASIMTUFII | OTSUKA PHARMACEUTICAL CO LTD | Suspension (Extended-Release) | ARIPIPRAZOLE 720 MG | Marketed |
| 02554577 | ABILIFY ASIMTUFII | OTSUKA PHARMACEUTICAL CO LTD | Suspension (Extended-Release) | ARIPIPRAZOLE 960 MG | Marketed |
| 02420872 | ABILIFY MAINTENA | OTSUKA PHARMACEUTICAL CO LTD | Kit; Powder For Suspension (Sustained-Release | ARIPIPRAZOLE 400 MG | Marketed |
| 02420864 | ABILIFY MAINTENA | OTSUKA PHARMACEUTICAL CO LTD | Powder For Suspension (Sustained-Release; Kit | ARIPIPRAZOLE 300 MG | Marketed |
| 02448211 | AG-ARIPIPRAZOLE | ANGITA PHARMA INC. | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02448173 | AG-ARIPIPRAZOLE | ANGITA PHARMA INC. | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02448246 | AG-ARIPIPRAZOLE | ANGITA PHARMA INC. | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02471094 | APO-ARIPIPRAZOLE | APOTEX INC | Tablet | ARIPIPRAZOLE 5 MG | Marketed |
| 02471086 | APO-ARIPIPRAZOLE | APOTEX INC | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02471124 | APO-ARIPIPRAZOLE | APOTEX INC | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02471132 | APO-ARIPIPRAZOLE | APOTEX INC | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02471116 | APO-ARIPIPRAZOLE | APOTEX INC | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02471108 | APO-ARIPIPRAZOLE | APOTEX INC | Tablet | ARIPIPRAZOLE 10 MG | Marketed |
| 02506750 | ARIPIPRAZOLE | SANIS HEALTH INC | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02460084 | AURO-ARIPIPRAZOLE | AURO PHARMA INC | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02460076 | AURO-ARIPIPRAZOLE | AURO PHARMA INC | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02460068 | AURO-ARIPIPRAZOLE | AURO PHARMA INC | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02460041 | AURO-ARIPIPRAZOLE | AURO PHARMA INC | Tablet | ARIPIPRAZOLE 10 MG | Marketed |
| 02460033 | AURO-ARIPIPRAZOLE | AURO PHARMA INC | Tablet | ARIPIPRAZOLE 5 MG | Marketed |
| 02460025 | AURO-ARIPIPRAZOLE | AURO PHARMA INC | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02561034 | JAMP ARIPIPRAZOLE ORAL SOLUTION | JAMP PHARMA CORPORATION | Solution | ARIPIPRAZOLE 1 MG | Approved |
| 02483602 | MINT-ARIPIPRAZOLE | MINT PHARMACEUTICALS INC | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02483556 | MINT-ARIPIPRAZOLE | MINT PHARMACEUTICALS INC | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02483564 | MINT-ARIPIPRAZOLE | MINT PHARMACEUTICALS INC | Tablet | ARIPIPRAZOLE 5 MG | Marketed |
| 02483572 | MINT-ARIPIPRAZOLE | MINT PHARMACEUTICALS INC | Tablet | ARIPIPRAZOLE 10 MG | Marketed |
| 02483580 | MINT-ARIPIPRAZOLE | MINT PHARMACEUTICALS INC | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02483599 | MINT-ARIPIPRAZOLE | MINT PHARMACEUTICALS INC | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02472260 | NRA-ARIPIPRAZOLE | NORA PHARMA INC | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02472252 | NRA-ARIPIPRAZOLE | NORA PHARMA INC | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02472244 | NRA-ARIPIPRAZOLE | NORA PHARMA INC | Tablet | ARIPIPRAZOLE 10 MG | Marketed |
| 02472201 | NRA-ARIPIPRAZOLE | NORA PHARMA INC | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02472279 | NRA-ARIPIPRAZOLE | NORA PHARMA INC | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02466643 | PMS-ARIPIPRAZOLE | PHARMASCIENCE INC | Tablet | ARIPIPRAZOLE 5 MG | Marketed |
| 02466686 | PMS-ARIPIPRAZOLE | PHARMASCIENCE INC | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02466694 | PMS-ARIPIPRAZOLE | PHARMASCIENCE INC | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02466678 | PMS-ARIPIPRAZOLE | PHARMASCIENCE INC | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02466651 | PMS-ARIPIPRAZOLE | PHARMASCIENCE INC | Tablet | ARIPIPRAZOLE 10 MG | Marketed |
| 02466635 | PMS-ARIPIPRAZOLE | PHARMASCIENCE INC | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02479397 | RIVA-ARIPIPRAZOLE | LABORATOIRE RIVA INC. | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02479354 | RIVA-ARIPIPRAZOLE | LABORATOIRE RIVA INC. | Tablet | ARIPIPRAZOLE 5 MG | Marketed |
| 02479370 | RIVA-ARIPIPRAZOLE | LABORATOIRE RIVA INC. | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02479389 | RIVA-ARIPIPRAZOLE | LABORATOIRE RIVA INC. | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02473666 | SANDOZ ARIPIPRAZOLE | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 5 MG | Marketed |
| 02473658 | SANDOZ ARIPIPRAZOLE | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 2 MG | Marketed |
| 02473704 | SANDOZ ARIPIPRAZOLE | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 30 MG | Marketed |
| 02473690 | SANDOZ ARIPIPRAZOLE | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 20 MG | Marketed |
| 02473682 | SANDOZ ARIPIPRAZOLE | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 15 MG | Marketed |
| 02473674 | SANDOZ ARIPIPRAZOLE | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 10 MG | Marketed |
| 02554550 | SOLUFY | ORIMED PHARMA INC | Solution | ARIPIPRAZOLE 1 MG | Marketed |
| 02475081 | SANDOZ ARIPIPRAZOLE TABLET | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 5 MG | Cancelled Pre Market |
| 02475103 | SANDOZ ARIPIPRAZOLE TABLET | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 10 MG | Cancelled Pre Market |
| 02475146 | SANDOZ ARIPIPRAZOLE TABLET | SANDOZ CANADA INCORPORATED | Tablet | ARIPIPRAZOLE 30 MG | Cancelled Pre Market |
| 02464152 | TEVA-ARIPIPRAZOLE | TEVA CANADA LIMITED | Tablet | ARIPIPRAZOLE 5 MG | Cancelled Post Market |
| 02464144 | TEVA-ARIPIPRAZOLE | TEVA CANADA LIMITED | Tablet | ARIPIPRAZOLE 2 MG | Cancelled Post Market |
| 02464187 | TEVA-ARIPIPRAZOLE | TEVA CANADA LIMITED | Tablet | ARIPIPRAZOLE 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37136 | 2026-03-18 | New Drug Submission (NDS) |
International API supply for ARIPIPRAZOLE
16 valid EDQM Certificates of Suitability from 15 holders. 54 active FDA Drug Master Files.
Request a quote for ODAN-ARIPIPRAZOLE SOLUTION